Sonoma Pharmaceuticals
SNOA
12 hedge funds and large institutions have $71.5K invested in Sonoma Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 9 → 12 (+3)
32% more capital invested
Capital invested by funds: $54.2K → $71.5K (+$17.3K)
0.54% more ownership
Funds ownership: 1.5% → 2.04% (+0.54%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$45.5K |
| 2 |
HF
HRT Financial
New York
|
+$32K |
| 3 |
Citigroup
New York
|
+$2.19K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$42.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $36.8K | +$45.5K | +16,805 | New |
|
|
HF
2
HRT Financial
New York
| $25K | +$32K | +11,843 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.06K | -$42.1K | -15,578 | -89% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3.17K | -$2.6K | -960 | -40% |
|
|
5
Citigroup
New York
| $1.78K | +$2.19K | +811 | New |
|
6
JP Morgan Chase
New York
| $302 | – | – | – |
|
7
BlackRock
New York
| $247 | – | – | – |
|
8
US Bancorp
Minneapolis,
Minnesota
| $55 | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| $32 | +$8 | +3 | +25% |
|
|
AF
10
Allworth Financial
Folsom,
California
| $12 | – | – | – |
|
11
Morgan Stanley
New York
| $9 | – | – | – |
|
|
DB
12
Danske Bank
Copenhagen K,
Denmark
| $2 | – | – | – |
|
SNOA Hedge Fund Activity: Q1 2025 in Review
12 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2025, worth a combined $71.5K — up 32% from $54.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SNOA positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $45.5K. The largest seller was UBS Group, cutting an estimated $42.1K.
- 12 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2025, up from 9 in Q4 2024.
- Funds reported $71.5K of Sonoma Pharmaceuticals stock for Q1 2025, up 32% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest Sonoma Pharmaceuticals buyer in Q1 2025 was Geode Capital Management, an estimated $45.5K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $42.1K sold.
Based on aggregated 13F filings for Q1 2025.